By Jacqueline Bell ( October 25, 2011, 1:41 PM EDT) -- Pharmaceutical companies racked up record numbers of so-called reverse payment patent settlements in 2011 designed to delay the release of a rival generic drug, the Federal Trade Commission said Tuesday, calling it an anti-competitive practice that costs consumers and the U.S. government billions....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.